Patient and physician preferences for atopic dermatitis injection treatments in Japan

Okubo, Yukari; Ho, Kerrie-Anne; Fifer, Simon; Fujita, Hiroyuki; Oki, Yasuyo; Taguchi, Yurie

doi:10.1080/09546634.2019.1623860

Cited by 19 publications

(28 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously reported, the safety profile of abrocitinib in JADE COMPARE was consistent with previous studies, and abrocitinib demonstrated rapid improvement in the signs and symptoms of AD compared with placebo 16 . Swift and clinically meaningful improvements in severity of patient‐reported signs and symptoms are desirable in patients with AD 13,26,27 . More than half of patients with moderate‐to‐severe AD have inadequately controlled disease despite the use of currently available therapies 28 .…”

Section: Discussionsupporting

confidence: 83%

“…Furthermore, dupilumab is administered by subcutaneous injection; many patients prefer therapies with less invasive routes of administration (i.e. oral administration) 13 . Many more systemic treatments are becoming available for the treatment of moderate‐to‐severe AD, with baricitinib, tralokinumab, upadacitinib, and abrocitinib recently gaining approval in some geographic regions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis

Thyssen

Yosipovitch

Paul³

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background In JADE COMPARE, abrocitinib improved severity of atopic dermatitis (AD) and demonstrated rapid itch relief. Objectives We examined clinically meaningful improvements in selected patient‐reported outcomes (PROs). Methods JADE COMPARE was a multicentre, phase 3 randomized, double‐blind, placebo‐controlled trial. Adults with moderate‐to‐severe AD were randomized 2:2:2:1 to receive 16 weeks of oral abrocitinib 200 or 100 mg once daily, dupilumab 300 mg subcutaneous injection every 2 weeks, or placebo, with background topical therapy. PROs included Dermatology Life Quality Index (DLQI), Patient‐Oriented Eczema Measure (POEM), Night Time Itch Scale (NTIS), Pruritus and Symptoms Assessment for Atopic Dermatitis, Patient Global Assessment, SCORing Atopic Dermatitis, and Hospital Anxiety and Depression Scale. Results At week 16, the proportion of patients achieving POEM scores <3 was 21.3% and 11.7% for 200 and 100 mg abrocitinib, 12.4% for dupilumab, and 4.8% for placebo (vs. abrocitinib, P < 0.0001 and P = 0.04). Proportion achieving ≥4‐point improvement from baseline in NTIS severity was 64.3% and 52.4% for 200 and 100 mg abrocitinib, 54.0% for dupilumab, and 34.4% for placebo (vs. abrocitinib, P < 0.0001 and P = 0.007). Proportion achieving ≥4‐point improvement from baseline in DLQI was 85.0% and 74.4% for 200 and 100 mg abrocitinib, 83.4% for dupilumab, and 59.7% for placebo (vs. abrocitinib, P < 0.0001 and P = 0.005). Conclusion Significant improvements in PROs were demonstrated with both abrocitinib doses vs. placebo, and abrocitinib 200 mg provided numerically greater effects compared with dupilumab in patients with moderate‐to‐severe AD.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis

Thyssen

Yosipovitch

Paul³

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…This is in line with the results of a similar study performed in Japan, in which physicians were more likely to value the efficacy of biological therapies in the treatment of AD [ 38 ]. In terms of AEs, another study in the USA comparing physician and patient preferences reported that the former are more concerned with the possibility of long-term AEs than the latter [ 39 ].…”

Section: Discussionsupporting

confidence: 89%

Quantifying Physician Preferences for Systemic Atopic Dermatitis Treatments Using a Discrete-Choice Experiment

Carrillo

Torres

Calzada

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction As research continues, new drugs will no doubt be added to the current pool of treatments for moderate-to-severe atopic dermatitis (AD). This raises the need for studies to determine prescriber preferences for different pharmacological options and the factors that influence their choice of treatment. Here we aim to explore physician preferences in the systemic treatment of moderate-to-severe AD, identify the sociodemographic characteristics that can influence physician preferences, and evaluate their satisfaction with current AD therapies. Methods A discrete-choice experiment (DCE) survey was administered to physicians treating patients with AD in Spain. Results were analyzed using a conditional logit model to estimate the relative importance of each attribute and the maximum risk accepted to achieve therapeutic benefit. Results A total of 28 respondents completed the DCE survey (67.9% female, mean age 45.9 years). Participants identified objective clinical efficacy and risk of severe adverse events (AEs) as the most important attributes, followed by improvement in sleep and pruritus and faster onset of action from the start of the treatment. Respondents gave less importance to mode of administration and therapeutic benefit in other atopic conditions. Respondents were willing to accept an increased risk of severe AEs and mild-to-moderate AEs leading to treatment discontinuation due to intolerance in order to obtain improvements in efficacy, sleep, and pruritus, and long-term clinical benefit. Conclusion Our findings can help prescribers choose the most appropriate systemic AD therapy. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-022-00723-z.

show abstract

“…This was one of the first studies (first in the United States and the United Kingdom) to our knowledge to assess patient preferences for systemic treatment options for moderate-to-severe AD. A study conducted in Japan, which assessed preferences among patients with moderate-tosevere AD focused more on differences between preferences of patients and physicians, specifically regarding attributes of injection treatments [23]. Qualitative interviews from our study indicated that for systematic treatments, respondents value probability of skin clearance, time to onset of itch relief, convenient dosing/administration schedule, and avoidance of safety risks.…”

Section: Discussionmentioning

confidence: 87%

“…Unfortunately, no data exist on patient preferences for systemic AD treatments in the United States and Europe. One study was conducted in Japan, which reported that the top three attributes for the patients are risk of mild side effects, time until response, and efficacy of reducing itching; however, this study focused more on the differences between the top attributes for patients and physicians for injection treatments [23].…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment

Boeri¹,

Sutphin

Hauber

et al. 2020

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Objectives: To identify meaningful treatment attributes and quantify patient preferences for attributes of systemic atopic dermatitis (AD) treatments. Materials and Methods: Qualitative interviews were conducted with adults with moderate-tosevere AD (N = 21) to identify AD treatment attributes that patients consider most important and inform attribute selection for an online discrete-choice experiment (DCE) survey administered to patients in the United States with moderate-to-severe AD. Participants identified probability of clear/almost clear skin at 16 weeks, time to itch relief, mode of administration, and safety risks as very important. DCE data were analyzed using a random-parameters logit model to estimate the relative importance of treatment attributes and maximum acceptable risk. Results: A total of 320 respondents completed the DCE survey (74% female; mean age, 35 years). Annual risk of malignancy was the most important attribute, followed by mode of administration, probability of clear skin at 16 weeks, and time to onset of itch relief. Respondents preferred daily oral treatment over injectable treatment. Respondents were willing to accept increases in adverse event risks for improvements in efficacy and mode of administration. Conclusion: The findings of this study can help inform joint patient-physician decision making in managing moderate-to-severe AD.

show abstract

Patient and physician preferences for atopic dermatitis injection treatments in Japan

Cited by 19 publications

References 28 publications

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis

Quantifying Physician Preferences for Systemic Atopic Dermatitis Treatments Using a Discrete-Choice Experiment

Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment

Contact Info

Product

Resources

About